| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Sanitam Partners LLC | 10% | -59% | $10,262,939 | +$9,526,394 | 17,104,899 | +1293% | STERN ADAM K | 08 Apr 2025 |
| Pembroke & Partners LLC | 10% | -50% | $10,137,427 | +$9,526,394 | 16,895,712 | +1559% | Robert J. Eide | 08 Apr 2025 |
| Lazar David E. | 9.8% | $517,750 | 545,000 | Lazar David E. | 15 Aug 2025 | |||
| Hezbay Holdings LLC | 5% | $533,066 | 253,841 | Hezbay Holdings LLC | 25 Sep 2025 | |||
| 111 Equity Group | 3.6% | -31% | $110,183 | -$47,617 | 183,639 | -30% | 111 Equity Group LLC | 13 Feb 2025 |
As of 30 Sep 2025, 28 institutional investors reported holding 330,108 shares of Matinas BioPharma Holdings, Inc. - Common Stock, par value $0.0001 per share (MTNB). This represents 6.5% of the company’s total 5,086,994 outstanding shares.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 32,520 | $20,162 | $0.61 | 2 | |
| 2025 Q3 | 330,108 | $617,696 | +$101,472 | $1.89 | 28 |
| 2025 Q2 | 276,386 | $254,142 | -$21,440 | $0.89 | 24 |
| 2025 Q1 | 320,149 | $166,481 | -$25,649 | $0.52 | 23 |
| 2024 Q4 | 369,473 | $194,080 | -$555,641 | $0.51 | 20 |
| 2024 Q3 | 535,167 | $1,894,530 | +$1,718,769 | $3.54 | 16 |